CD28 and relapsing-remitting multiple sclerosis: Finally, treatment of CD4+ T cells from RRMS patients with a class 1A PI3K inhibitor strongly impaired CD28-induced glycolysis, c-myc and Glut1 expressions, as well as the up-regulation of pro-inflammatory cytokines.